On 27 October 2006, orphan designation (EU/3/06/409) was granted by the European Commission to Erytech Pharma S.A., France, for L-asparaginase encapsulated in erythrocytes for the treatment of acute lymphoblastic leukaemia.
L-asparaginase encapsulated in erythrocytes
Treatment of acute lymphoblastic leukaemia
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.